Lupus Trials

​The Division of Rheumatology strives to understand more about lupus through research.  Please see the list below, which summarizes the st​udies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 


Study Name/IRB​#/PIBrief Description​Basic Eligibility​ CriteriaContact​
SMILE (Study of Anti-Malarials in Incomplete Lupus Erythematosus)
Susan Boackle, MD
 ​Use of an approved medication (hydroxychloroquine) to prevent development of additional clinical and immunologic features of SLE. This study includes a placebo group.
  • Teens or adults (ages 15-49) with an ANA titer of 1:80 or greater, plus one to two additional features of SLE.

303-724-0581 or 303-724-3614

Or email Karen Franklin or Prakriti Joshee

Karen Franklin
Prakriti Joshee


Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.